MIAMI--(BUSINESS WIRE)--June 30, 2006--Reissuing release to correct ticker symbol for searching purposes. The corrected release reads: DOR BioPharma, Inc. (OTCBB:DORB - News; “DOR”, or the “Company”) announced today that it is providing new guidance on the filing of its New Drug Application (“NDA”) and Marketing Authorization Application (“MAA”) submissions for orBec® for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD). DOR’s target for submission of the NDA for orBec® is now in the July - August timeframe of 2006. DOR’s filing target in the EMEA remains by the end of the 3rd Quarter 2006.
